Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer. (Q44786676)

From Wikidata

Jump to navigation Jump to search

scientific article published on 13 May 2016

Language	Label	Description	Also known as
English	Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer.	scientific article published on 13 May 2016

Statements

scholarly article

1 reference

Europe PubMed Central

6 December 2017

Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

author name string

A Argiris

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

J E Bauman

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

J Ohr

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

W E Gooding

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

D E Heron

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

U Duvvuri

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

G J Kubicek

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

D M Posluszny

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

M Vassilakopoulou

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

S Kim

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

J R Grandis

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

J T Johnson

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

M K Gibson

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

D A Clump

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

J T Flaherty

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

B Branstetter

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

R L Ferris

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

13 May 2016

1 reference

Europe PubMed Central

6 December 2017

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

27

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

1594-1600

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

Human papillomavirus and survival of patients with oropharyngeal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With [...]

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

Pemetrexed in head and neck cancer: a systematic review

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

Survivorship and Quality of Life in Head and Neck Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW204

21 January 2018

A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/27177865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/27177865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Performance Status Scale for Head and Neck Cancer Patients and the Functional Assessment of Cancer Therapy-Head and Neck Scale. A study of utility and validity.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27177865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of head and neck and esophageal xenografts employing Alimta and concurrent ionizing radiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/27177865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab: current indications and future development for management of solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/27177865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27177865

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDW204

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6279075&resulttype=core&format=json

13 May 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44786676&oldid=1623016598"